Your account is not claimed yet. You can sign up with ORCID to claim your account.

Dhruvitkumar S Sutaria

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Venues

JCO clinical cancer informatics

Pharmaceutics

Antimicrobial agents and chemotherapy

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

David W Pook, Daniel M Geynisman, Joan Carles, Filippo G De Braud, Anthony M Joshua, José Luis Pérez-Gracia, Casilda Llácer Pérez, Sang Joon Shin, Bruno Fang, Minal Barve, Maruzzo Marco, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S Sutaria, Howard Gurney
A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
Dhruvitkumar S Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles, Jorge Daniel Gallo, Rucha Sane
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. Pharmaceutics 14 (10) (2022)
Rucha Sane, Vikram Malhi, Dhruvitkumar S Sutaria, Eunpi Cho, Patrick Twomey, Christopher Craggs, Jianshuang Wang, Adam Harris, Luna Musib
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using Two Methods of Classification of Hepatic Function. Journal of clinical pharmacology (2021)
Nirav R Shah, Juergen B Bulitta, Martina Kinzig, Cornelia B Landersdorfer, Yuanyuan Jiao, Dhruvitkumar S Sutaria, Xun Tao, Rainer Höhl, Gerhard Bringmann, Frieder Kees, Ulrich Stephan, Fritz Sörgel
Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics 11 (6) (2019)
Dhruvitkumar S Sutaria, Bartolome Moya, Kari B Green, Tae Hwan Kim, Xun Tao, Yuanyuan Jiao, Arnold Louie, George L Drusano, Juergen B Bulitta
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 62 (6) (2018)
Dhruvitkumar S Sutaria, Jinmai Jiang, Ola A Elgamal, Steven M Pomeroy, Mohamed Badawi, Xiaohua Zhu, Ryan Pavlovicz, Ana Clara P Azevedo-Pouly, Jeffrey Chalmers, Chenglong Li, Mitch A Phelps, Thomas D Schmittgen
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. Journal of extracellular vesicles 6 (1) (2017)
Dhruvitkumar S Sutaria, Jinmai Jiang, Ana Clara P Azevedo-Pouly, Eun Joo Lee, Megan R Lerner, Daniel J Brackett, Jo Vandesompele, Pieter Mestdagh, Thomas D Schmittgen
Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. Non-coding RNA 3 (3) (2017)

Dhruvitkumar S Sutaria.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Dhruvitkumar S Sutaria